Summary
Metastasizing cancer cells can invade the extracellular matrix using plasma membrane protrusions, termed invadopodia, that contact and dissolve the matrix. Various membrane associated proteases localized on the invadopodial membranes are responsible for the extracellular matrix degradation. Work from our laboratory shows that secreted proteases including Gelatinase A, and high molecular weight integral membrane proteases are associated with cell surface invadopodia. Three cell types, including chicken embryonic cells transformed by Rous sarcoma virus, human malignant melanoma cell line LOX, and human breast carcinoma cell line MDA-MB-231, retain the invasive phenotypein vitro, express invadopodia, degrade and enter into a fibronectin-rich collagenous matrix. We suggest that invadopodium-associated proteases are ideal targets for the diagnosis and treatment of cancer as their presence in association with primary tumors may signal increased metastatic potential. An approach toward the development of new prognostic markers for breast malignancy involved production of monoclonal antibodies directed against membrane proteases in a mixture of glycoproteins. Double immunofluorescent technique using a known invadopodium marker is designed to select specific monoclonal antibodies colocalizing at the invasion front, on invadopodia of cancer cells. Membrane protease accessibility at the cell surface can therefore be exploited for therapeutic advances by the development of specific antibodies and inhibitors that block their activities, and by the use of monoclonal antibodies to target cytotoxic molecules to micrometastases. Also, this same accessibility may potentially be used to detect surface proteases on micrometastases or to detect components shed by micrometastases in serum.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Harris JR, Lippman ME, Veronesi U, Willett W: Breast Cancer (Part III). N. Engl J Med 327: 473–480, 1992
McGuire WL, Clark GM: Prognostic Factors and Treatment Decisions in Axillary Node-Negative Breast Cancer. N Engl J Med 326: 1756–1761, 1992
Rochefort H: Cathepsin D in breast cancer: A tissue marker associated with metastasis. Eur J Cancer [A] 28A: 1780–1783, 1992
Chen W-T: Membrane proteases: roles in tissue remodeling and tumour invasion. Curr Opin Cell Biol 4: 802–809, 1992
Mignatti P, Rifkin DB: Biology and biochemistry of proteinases in tumor invasion. Physiol Rev 73: 161–195, 1993
Chen W-T: Proteolytic activity of specialized surface protrusions formed at rosette contact sites of transformed cells. J Exp Zool 251: 167–185, 1989
David-Pfeuty T, Singer SJ: Altered distributions of the cytoskeletal proteins vinculin and alpha-actinin in cultured fibroblasts transformed by Rous sarcoma virus. Proc Natl Acad Sci USA 77: 6687–6691, 1980
Tarone G, Cirillo D, Giancotti FG, Comoglio PM, Marchisio PC: Rous sarcoma virus-transformed fibroblasts adhere primarily at discrete protrusions of the ventral membrane called podosomes. Exp Cell Res 159: 141–1547, 1985
Chen W-T, Olden K, Bernard BA, Chu F-F: Expression of transformation-associated protease(s) that degrade fibronectin at cell contact sites. J Cell Biol 98: 1546–1555, 1984
Chen W-T, Chen JM, Parsons SJ, Parsons JT: Local degradation of fibronectin at sites of expression of the transforming gene product pp60src. Nature 316: 156–158, 1985
Chen W-T: Transmembrane interactions at cell adhesion and invasion sites. Cell Diff Dev 32: 329–336, 1990
Kelly T, Mueller SC, Yeh Y, Chen W-T: Invadopodia promote proteolysis of a wide variety of extracellular matrix proteins. J Cell Physiol 1993 (in press)
Mueller SC, Kelly T, Dai MZ, Dai HN, Chen W-T: Dynamic cytoskeleton-integrin associations induced by cell binding to immobilized fibronectin. J Cell Biol 109: 3455–3464, 1989
Mueller SC, Yeh Y, Chen W-T: Tyrosine phosphorylation of membrane proteins mediates cellular invasion by transformed cells. J Cell biol 119: 1309–1325, 1992
McCarthy JB, Skubitz APN, Iida J, Mooradian DL, Wilke MS, Furcht LT: Tumor cell adhesive mechanisms and their relationship to metastasis. Semin Cancer Bil 2: 155–167, 1991
Monsky WL, Kelly T, Lin C-Y, Yeh Y, Stetler-Stevenson WG, Mueler SC, Chen W-T: Binding and localization ofM r 72,000 matrix metalloproteinase at cell surface invadopodia. Cancer Res 53: 3159–3164, 1993
Liotta LA, Steeg PS, Stetler-Stevenson WG: Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 64: 327–336, 1991
Goretzki L, Schmitt M, Mann K, Calvete J, Chucholowski N, Kramer M, Günzler WA, Jänicke F, Graeff H: Effective activation of the proenzyme form of the urokinase-type plasminogen activator (pro-uPA) by the cysteine protease cathepsin L. FEBS Lett 297: 112–118, 1992
Azzam HS, Thompson EW: Collagen-induced activation of the M(r) 72,000 type IV collagenase in normal and malignant human fibroblastoid cells. Cancer Res 52: 4540–4544, 1992
Wolf C, Rouyer N, Lutz Y, Adida C, Loriot M, Bellocq J-P, Chambon P, Basset P: Stromelysin 3 belongs to a subgroup of proteinases expressed in breast carcinoma fibroblastic cells and possibly implicated in tumor progression. Proc Natl Acad Sci USA 90: 1843–1847, 1993
Kute TE, Shao Z-M, Sugg NK, Long RT, Russell GB, Case LD: Cathepsin D as a prognostic indicator for node-negative breast cancer patients using both immunoassays and enzymatic assays. Cancer Res 52: 5198–5203, 1992
Vecchio SD, Stoppelli MP, Caniero MV, Fonti R, Massa O, Li PY, Botti G, Cerra M, D'Aiuto G, Esposito G, Salavatore M: Human urokinase receptor concentration in malignant and benign breast tumors byin vitro quantitative autoradiography: comparison with urokinase levels. Cancer Res 53: 3198–3206, 1993
Pyke C, Græm N, Ralfkiær E, Ronne E, Hoyer-Hansen G, Brünner N, Dano K: Receptor for urokinase is present in tumor-associated macrophages in ductal breast carcinoma. Cancer Res 53: 1911–1915, 1993
Ward RV, Atkinson SJ, Slocombe PM, Docherty AJP, Reynolds JJ, Murphy G: Tissue inhibitor of metalloproteinases-2 inhibits the activation of 72 kDa progelatinase by fibroblast membranes. Biochim Biophys Acta Protein Struct Mol Enzymol 1079: 242–246, 1991
Murphy G, Willenbrock F, Ward RV, Cockett MI, Eaton D, Docherty AJP: TheC-terminal domain of 72 kDa gelatinase A is not required for catalysis, but is essential for membrane activation and modulates interactions with tissue inhibitors of metalloproteinases. Biochem J 283: 637–641, 1992
Emonard HP, Remacle AG, Noël AC, Grimaud J-A, Stetler-Stevenson WG, Foidart J-M: Tumor cell surface-associated binding site for theM r 72,000 type IV collagenase. Cancer Res 52: 5845–5848, 1992
Chen JM, Chen W-T: Fibronectin-degrading proteases from the membranes of transformed cells. Cell 48: 193–203, 1987
Aoyama A, Chen W-T: A 170-kDa membrane-bound protease is associated with the expression of invasiveness by human malignant melanoma cells. Proc Natl Acad Sci USA 87: 8296–8300, 1990
Zucker S, Wieman JM, Lysik RM, Wilkie DP, Ramamurthy N, Lane B: Metastatic mouse melanoma cells release collagen-gelatin degrading metalloproteinases as components of shed membrane vesicles. Biochim Biophys Acta 924: 225–237, 1987
Shipp MA, Vijayaraghavan J, Schmidt EV, Masteller EL, D'Adamio L, Hersh LB, Reinherz EL: Common acute lymphoblastic leukemia antigen (CALLA) is active neutral endopeptidase 24.11 (‘enkephalinase’): direct evidence by cDNA transfection analysis. Proc Natl Acad Sci USA 86: 297–301, 1989
Marguet D, Bernard AM, Vivier I, Darmoul D, Naquet P, Pierres M: cDNA cloning for mouse thymocyte-activating molecule. A multifunctional ecto-dipeptidyl peptidase IV (CF26) included in a subgroup of serine proteases. J Biol Chem 267: 2200–2208, 1992
Piazza GA, Callanan HM, Mowery J, Hixson DC: Evidence for a role of dipeptidyl peptidase IV in fibronectin-mediated interactions of hepatocytes with extracellular matrix. Biochem J 262: 327–334, 1989
Hanski C, Huhle T, Gossrau R, Reutter W: Direct evidence for the binding of rat liver DPP IV to collagenin vitro. Exp Cell Res 178: 64–72, 1988
Urade M, Komatsu M, Yamamoka M, Fukasawa K, Harada M, Mima T, Matsuya T: Serum dipeptidyl peptidase activities as a possible marker of oral cancer. Cancer 64: 1274–1280, 1989
Yoshioka M, Erickson RH, Matsumoto H, Gum E, Kim YS: Expression of dipeptidyl aminopeptidase IV during enterocytic differentiation of human colon cancer (Caco-2) cells. Int J Cancer 47: 916–921, 1991
Kotani T, Asada Y, Aratake Y, Umeke K, Yamamoto I, Tokudome R, Hirai K, Kuma K, Konoe K, Araki Y, Ohtaki S: Diagnostic usefulness of dipeptidyl aminopeptidase IV monoclonal antibody in paraffin-embedded thyroid follicular tumours. J Pathol 168: 41–45, 1992
Johnson RC, Zhu D, Augustin-Voss HG, Pauli BU: Lung endothelial dipeptidyl peptidase IV is an adhesion molecule for lung-metastatic rat breast and prostate carcinoma cells. J Cell Biol 121: 1423–1432, 1993
DeClerck YA, Perez N, Shimada H, Boone TC, Langley KE, Taylor SM: Inhibition of invasion and metastasis in cells transfected with an inhibitor of metalloproteinases. Cancer Res 51: 701–708, 1992
Melchiori A, Albini A, Ray JM, Stetler-Stevenson WG: Inhibition of tumor cell invasion by a highly conserved peptide sequence from the matrix metalloproteinase enzyme prosegment. Cancer Res 52: 2353–2356, 1992
Ossowski L, Reich E: Changes in malignant phenotype of a human carcinoma conditioned by growth environment. Cell 33: 323–333, 1983
Hearing VJ, Law LW, Corti A, Appella E, Blasi F: Modulation of metastatic potential by cell surface urokinase of murine melanoma cells. Cancer Res 48: 1270–1278, 1988
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Chen, WT., Lee, CC., Goldstein, L. et al. Membrane proteases as potential diagnostic and therapeutic targets for breast malignancy. Breast Cancer Res Tr 31, 217–226 (1994). https://doi.org/10.1007/BF00666155
Issue Date:
DOI: https://doi.org/10.1007/BF00666155